Company intelligence / Profile preview
Beijing Shengshi Liangfang Pharmaceutical Technology
Beijing, Beijing, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Beijing Shengshi Liangfang Pharmaceutical Technology is a Chinese biotechnology company focused on the research and development of innovative small molecule drugs for metabolic diseases. The company's primary focus is on developing treatments for type 2 diabetes and obesity, with a pipeline featuring GLP-1 receptor agonists and DPP-4 inhibitors. Their lead candidate, SSLF-008, is an oral small molecule GLP-1 receptor agonist currently in clinical development. The company aims to provide more accessible and effective oral alternatives to injectable metabolic therapies.
- Therapeutic areas
- Endocrinology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Beijing Shengshi Liangfang Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Shengshi Liangfang Pharmaceutical Technology.